FATE · XBRL financial data

Fate Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FATE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	31	56	96	64	14	7
Research and development	126	216	320	173	135	108
General and administrative	34	57	84	81	74	47
Total operating expenses	160	273	405	254	224	154
Operating income (loss)	(128)	(217)	(308)	(191)	(210)	(148)
Interest income	2	1	6	17	17	11
Interest expense	0	0	—	—	—	—
Other income (expense)	(45)	5	27	30	24	11
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(173)	(212)	(282)	(161)	(186)	(136)
Earnings per share, basic USD per share	(2.10)	(2.24)	(2.91)	(1.64)	(1.64)	(1.15)
Earnings per share, diluted USD per share	(2.10)	(2.24)	(2.91)	(1.64)	(1.64)	(1.15)
Weighted average shares, basic millions of shares	82	95	97	98	114	119
Weighted average shares, diluted millions of shares	82	95	97	98	114	119

Fiscal years (FATE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	167	134	61	42	36	47
Short-term investments	—	482	375	273	243	157
Accounts receivable	6	9	38	2	4	1
Prepaid and other current assets	6	9	27	15	9	4
Total current assets	494	633	502	332	292	209
Property and equipment, net	32	92	110	97	64	57
Right-of-use asset	67	71	66	62	47	42
Total assets	622	921	706	506	441	319
Accounts payable	6	9	8	5	9	3
Accrued liabilities	16	42	54	28	21	20
Total current liabilities	86	81	114	39	39	36
Lease liability, non-current	94	109	104	97	78	73
Accumulated deficit	(557)	(769)	(1,051)	(1,212)	(1,398)	(1,534)
Total stockholders' equity	384	679	484	368	319	207
Total liabilities and equity	622	921	706	506	441	319
Common shares outstanding (cover page) millions of shares	94	96	98	99	115	116

Fiscal years (FATE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(173)	(212)	(282)	(161)	(186)	(136)
Depreciation and amortization	3	6	14	18	19	13
Net cash from operating activities	(39)	(163)	(248)	(132)	(123)	(106)
Purchases of property and equipment	5	51	36	6	1	6
Net cash from investing activities	(161)	(324)	167	113	12	111
Proceeds from issuing common stock	189	412	—	—	—	—
Net cash from financing activities	283	453	9	0	100	5
Net change in cash	83	(34)	(72)	(20)	(11)	11

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Fate Therapeutics	32	2.1	(23)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Protalix BioTherapeutics	27	20	(10)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26	1.5	(23)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17	not reported	(15)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	1	not reported	(8.6)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Alector	60	3.3	(34)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33	14	(10)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
Galectin Therapeutics	13	not reported	(2.4)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	148	0	(21)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.